The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.

The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients with primary premature ejaculation.

Inclusion Criteria:

• A male regularly experiencing premature ejaculation
• 18 to 55 yrs old
• In a Stable relationship with one woman for at least 6 months